Because most patients with MG are on immunosuppressive or immunomodulatory therapies and may also have respiratory muscle weakness, there is a theoretical concern that MG/LEMS patients may be at higher risk of contracting the infection or experiencing severe manifestations of COVID-19. In addition, to date, peer reviewed published literature regarding COVID-19 in MG or in immunocompromised patients is lacking. In this very useful short communication, the International MG/COVID-19 Working Group has developed recommendations about the management of MG and LEMS patients during the COVID-19 pandemic. In particular, the MG expert panel suggests that therapy decisions should be individualized and made collaboratively between the patients with MG and his/her healthcare provider.
https://www.ncbi.nlm.nih.gov/pubmed/32247193
by Marialuisa Zedde and Francesco Cavallieri